改善RAS通路病变中的突触可塑性与认知功能:一项单中心、随机、双盲、平行组、安慰剂对照、交叉临床试验(SynCoRAS)
本研究为IIa期单中心随机双盲平行组安慰剂对照交叉临床试验,在神经纤维瘤病1型(NF1)和Noonan综合征(NS)患者中评估洛伐他汀(LOV)和拉莫三嗪(LTG)对突触可塑性和认知功能/警觉性的影响。受试者接受单剂量LTG 300 mg或安慰剂(I和III)、LOV 200 mg或安慰剂(II)每日4天,至少7天后交叉。计划随机28例,目标24例达到主要终点(突触可塑性变化)。
要点
- 在NS患者中评估LTG(方案I)和LOV(方案II)对突触可塑性和警觉性的影响。
- 在NF1患者中评估LTG(方案III)对突触可塑性的影响。
- 主要终点为突触可塑性变化,次要终点为注意力(TAP)和短间隔皮层抑制(SICI)差异。
核心结论
- 本研究旨在将动物研究中LOV和LTG改善突触可塑性及认知功能的发现转化至人类,探讨二者在RAS通路病变患者中对突触可塑性和认知功能/警觉性的作用。
- 近期LOV在NF1患者中的初步结果显示突触可塑性和认知功能改善,本试验将探究这些发现能否推广至NS患者。
- LTG可能是改善突触可塑性并继而改善认知功能的更有效且有前景的药物,预期两种药物均能改善突触可塑性和警觉性,警觉性改变可能是认知改善的前提条件。
研究设计与样本
- IIa期单中心、随机、双盲、平行组、安慰剂对照、交叉临床试验(SynCoRAS),包含方案I-III。
- NS患者接受LTG(方案I)和LOV(方案II)评估,NF1患者接受LTG(方案III)评估。
- 受试者接受单剂量LTG 300 mg或安慰剂(I和III)以及LOV 200 mg或安慰剂(II)每日4天,至少7天后交叉。
- 计划随机28例患者进入NS和NF1组,目标24例达到主要终点(突触可塑性变化)。
- 突触可塑性采用重复高频经颅磁刺激(TMS)方案即四脉冲θ爆发刺激(qTBS)评估,注意力采用注意力表现测试(TAP)评估。
主要发现
- 主要终点为突触可塑性变化;次要终点为注意力(TAP)以及安慰剂与试验药物(LTG和LOV)之间短间隔皮层抑制(SICI)的差异。
- 近期LOV在NF1患者中的初步结果显示突触可塑性和认知功能改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cognitive impairment is a common medical issue in rat sarcoma (RAS) pathway disorders, so-called RASopathies, like Neurofibromatosis type 1 (NF1) or Noonan syndrome (NS). It is presumed to be caused by impaired synaptic plasticity. In animal studies, pathway-specific pharmacological interventions with lovastatin (LOV) and lamotrigine (LTG) have been shown to improve synaptic plasticity as well as cognitive function. The aim of this clinical trial is to translate the findings of animal studies to humans and to probe the effect of lovastatin (NS) and lamotrigine (NS and NF1) on synaptic plasticity and cognitive function/alertness in RASopathies. METHODS: Within this phase IIa, monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial (syn. SynCoRAS), three approaches (approaches I-III) will be carried out. In patients with NS, the effect of LTG (approach I) and of LOV (approach II) is investigated on synaptic plasticity and alertness. LTG is tested in patients with NF1 (approach III). Trial participants receive a single dose of 300 mg LTG or placebo (I and III) and 200 mg LOV or placebo (II) daily for 4 days with a cross-over after at least 7 days. Synaptic plasticity is investigated using a repetitive high-frequency transcranial magnetic stimulation (TMS) protocol called quadri-pulse theta burst stimulation (qTBS). Attention is examined by using the test of attentional performance (TAP). Twenty-eight patients are randomized in groups NS and NF1 with n = 24 intended to reach the primary endpoint (change in synaptic plasticity). Secondary endpoints are attention (TAP) and differences in short interval cortical inhibition (SICI) between placebo and trial medication (LTG and LOV). DISCUSSION: The study is targeting impairments in synaptic plasticity and cognitive impairment, one of the main health problems of patients with RASopathies. Recent first results with LOV in patients with NF1 have shown an improvement in synaptic plasticity and cognition. Within this clinical trial, it is investigated if these findings can be transferred to patients with NS. LTG is most likely a more effective and promising substance improving synaptic plasticity and, consecutively, cognitive function. It is expected that both substances are improving synaptic plasticity as well as alertness. Changes in alertness may be a precondition for improvement of cognition. TRIAL REGISTRATION: The clinical trial is registered in ClinicalTrials.gov (NCT03504501; https://www. CLINICALTRIALS: gov ; date of registration: 04/11/2018) and in EudraCT (number 2016-005022-10).
引用
- Jung NH, Egert-Schwender S, Schossow B, et al. Improvement of synaptic plasticity and cognitive function in RASopathies-a monocentre, randomized, double-blind, parallel-group, placebo-controlled, cross-over clinical trial (SynCoRAS). Trials. 2023. PMID: 37280688. doi:10.1186/s13063-023-07392-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。